{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"}],"units":"Participants"}],"description":"Percentage of participants who died of any cause was reported.","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on safety population.","reportingStatus":"POSTED","timeFrame":"Baseline up to death from any cause (up to approximately 4 years)","title":"Percentage of Participants Who Died of Any Cause","type":"SECONDARY","unitOfMeasure":"percentage of participants"}